Biomarkers for non-invasive detection and classifform-control form-control ication of prostate cancer

  • Universidad de Granada
  • From Spain
  • Responsive
  • Patents for licensing

Summary of the technology

Three new biomarkers for the prognosis, stratification and cancer monitoring have been identified: PCA3, MRC2, and S100A4. These biomarkers could be detected by non-invasive methods, such as liquid biopsy, and be used as a component for kits and devices with the same purpose.

Universidad de Granada

Details of the Technology Offer

Prostate cancer is one of the most common death causes worldwide, and one of the most frequently diagnosed tumours in males in Spain. In spite of that, diagnosis tools for their detection are lacking and there are no adequate genetic biomarkers: nowadays, PSA is the most common biomarker, despite the high percentage of false positives and false negatives.

Regarding treatment choice, there are no tools that can determine which treatment is the most effective for each patient. With it, the standard treatment is androgen deprivation therapy (ADT), which causes many hormone resistance cases. Despite existing a good initial response, after 18-24 months of ADT therapy, prostate cancer progresses to the castration resistant prostate cancer (CRPC) phase, which has 16 to 18 months survival rate.

To overcome that, three new genetic biomarkers PCA3, MRC2, and S100A4 have been identified. They can be used to detect, classify and/or prevent prostate cancer. PCA3 non-coding RNA is specific of prostatic tissue and is overexpressed early in prostate cancers; an overexpression of MRC2 indicates a higher extracellular matrix remodelling rate, which will ease further metastasis; and S1004A gene is overexpressed when cancer is more aggressive and metastasis has already started.

In addition, the detection of these biomarkers can be performed using non-invasive methods, such as liquid biopsy, and would be ideal for the development of kits and devices for the prevention, diagnosis and stratification of prostate cancer.


  • Tissue and cancer specificity:PCA3 is expressed only in prostatic tissue, overcoming the main disadvantage of PSA, its lack of specificity.
  • High accuracy and early detection.PCA3 is overexpressed in more than 95% of primary prostate cancers.
  • Custom medicine. Expression levels of PCA3, MRC2, and S100A4 allow to know the type and stage of cancer, easing its classification and the choice of the most adequate treatment.
  • Non-invasive. All three biomarkers can be detected using non-invasive methods, such as liquid biopsy.
  • Real-time analysis. Since liquid biopsy is a non-invasive process, it allows multiple analysis along tumor process.
  • Simple method. The possibility of using a kit or device eases data obtaining to diagnose and predict this type of cancer.

Current development status

Laboratory prototypes






Desired business relationship

Patent licensing

Intellectual property status

  • Patent already applied for
  • Patent application number :P202230187

Related Keywords

  • Biological Sciences
  • Cytology, Cancerology, Oncology
  • Biology / Biotechnology
  • Medical/health
  • Medical Health related
  • Diagnostic
  • Molecular diagnosis
  • Oncology
  • prostate cancer

About Universidad de Granada

Granada University is one of the most important universities of Spain. The main goal is to transfer technology that our research groups, more than 500, are developing to the industries and companies which are able to take profit from them. It is a general University so Research and Development are offered in different fields like Health Science and Technology, Physics, Chemistry and Mathematics, Environment and Natural Resources, Biotechnology, Information and Communication Technologies, Social, Economic and Legal Sciences....

We hope you find technologies of your interest which will allow us working together in the near future.

Universidad de Granada

Never miss an update from Universidad de Granada

Create your free account to connect with Universidad de Granada and thousands of other innovative organizations and professionals worldwide

Universidad de Granada

Send a request for information
to Universidad de Granada

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support